伊利莉在2026年初报告了强的第四季度收益,提高了2026年的预测,尽管有竞争和分析师评级混合,但仍出现积极发展. Eli Lilly reported strong Q4 earnings in early 2026, raised 2026 guidance, and saw positive developments despite competition and mixed analyst ratings.

2026年初,伊利莉公司报告了强的第四季度收益,每股收益7.54美元和192.9亿美元收入,同比增长42.6%,并将2026年的EPS预测提高到33.5035美元. In early 2026, Eli Lilly reported strong Q4 earnings, with $7.54 EPS and $19.29 billion in revenue, a 42.6% year-over-year increase, and raised its 2026 EPS guidance to $33.50–$35.00. 股票的市值为8553. 5亿美元,收益比率为39. 45%. The stock, trading at $905.30, has a market cap of $855.35 billion and a P/E ratio of 39.45. 尽管分析师评价不一,Novo Nordisk的高剂量Wegovy也给公司带来了竞争压力,但该公司取得了积极进展,包括儿童类亚托皮性皮炎试验的顶级结果,吉姆·克莱默认可以及非GLP-1管道项目中的进步. Despite mixed analyst ratings and competitive pressures from Novo Nordisk’s higher-dose Wegovy, the company saw positive developments including top-line results from a pediatric atopic dermatitis trial, a Jim Cramer endorsement, and progress in non-GLP-1 pipeline programs. 机构活动包括减少Unique Wealth LLC的股权和增加GoalVest,GAMMA投资以及Foguth财富管理公司的持有. Institutional activity included reduced stakes by Unique Wealth LLC and increased holdings by GoalVest, GAMMA Investing, and Foguth Wealth Management. 利率仍为"中等买入",目标是1,221.44美元. The consensus rating remains “Moderate Buy” with a target of $1,221.44.